Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Nov 30, 2010
Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4--7 in Orlando.
Their findings suggest that both drugs, CYT387 and TG101348, effectively reduce spleen size and alleviate constitutional symptoms, major symptoms of this disorder, but that each have unique benefits.
Below, principal researcher Ayalew Tefferi, M.D., and lead investigator Animesh Pardanani, Ph.D., further discuss these studies.